Learning Center
Plans & pricing Sign in
Sign Out
Get this document free

NCI Cancer Bulletin NCI Cancer Bulletin Eliminating the Suffering and Death Due


									                                      NCI Cancer Bulletin                                  Eliminating the Suffering and Death Due to Cancer

                                                               Two New Studies Profile Prognostic
September 7, 2004
Volume 1 | Number 34

In this issue:
Two New Studies Profile
                                                               Factors for Breast Cancer
Prognostic Factors for Breast                                  Two new studies provide insight into           labeled monoclonal antibodies to
                                                               the use of new and standard prog-              distinguish cancerous epithelial cells
Director’s Update...1                                          nostic factors for women with breast           from leukocytes in a blood sample.
   A Vital Connection to the
    Cancer Community                                           cancer. The first, conducted by Dr.             The test was developed by the re-
                                                               Massimo Cristofanilli and colleagues           search sponsor, Immunicon Corp.
Cancer Research Highlights...3
   Selective Use of Patients from
                                                               at several prominent U.S. cancer               All 177 women in the study group
    High-Risk Clinics May Bias                                 research centers, confirms the long-            had metastatic breast cancer and
    Study Results                                              held hypothesis that the number of             were starting a new course of sys-
   Breast Cancer in African                                    cancer cells in the blood are a direct
    American Women                                                                                            temic treatment. The women began
                                                               indicator of disease severity. The             the study with standard imaging of
   Combination Therapy
    for Prostate Cancer Patients                               results are published in the August 19         metastatic sites and a baseline test
   High Burden of Illness Found                                New England Journal of Medicine.               for the number of cancer cells in their
    in Cancer Survivors
                                                               This research was performed using a            blood, followed by another blood
   Research Links Specific ABC
    Transporters and Drug Efficacy                               new test—the CellSearch System—                test approximately 4 weeks later and
NCI to Launch
                                                               which uses antibody-coated mag-                additional imaging around 10 weeks
Nanotechnology Initiative...4                                  netic beads followed by fluorescently           (continued on page 2)
A Conversation With...5
   Dr. John E. Niederhuber
                                                               A Vital Connection to the Cancer Community
                                      D ire ctor ’s Up d ate

Funding Opportunities...5
Featured Clinical Trial...6
   Prevention of Bone Fractures                                  New NCAB Members
    in Prostate Cancer Patients
Notes...7                                                        Dr. John E. Niederhuber         University of Wisconsin School of Medicine
                                                                 (reappointed as chair)
   New Information on Preven-
    tion Trials Available from NCI                               Ms. Kathryn Giusti              Multiple Myeloma Research Foundation
   Elizalde Named Deputy Direc-                                  Mr. David H. Koch               Koch Industries
    tor for Management
                                                                 Dr. Diana Montes de Oca Lopez   University of Miami School of Medicine
   Future Directions for Cancer
    Screening Promotion                                          Dr. Carolyn D. Runowicz         University of Connecticut Comprehensive Cancer Center
   Radiation Oncology Sciences                                   Dr. Daniel D. Von Hoff          Arizona Health Sciences Center’s Cancer Therapeutics Program
    Program Staff Visit Capitol Hill
   Reminder: Gerberding to Speak
    at NIH                                                     One of the most effective ways in               of the Department of Health and
                                                               which NCI interacts with the cancer            Human Services with regard to the
Featured Meetings...8
                                                               community is through our advisory              Institute’s strategic plan and its
                                                               boards. Next week, for instance, the           intramural and extramural research
                                                               National Cancer Advisory Board                 activities. The committee’s 18 mem-
A Publication of the                                           (NCAB) will meet for the third time            bers are appointed by the President.
National Cancer Institute                                      this year. Among the advisory boards           The NCAB also is distinct from other
                                                               and committees to NCI, the NCAB                NCI advisory boards in that it
National Institutes of Health                                  plays a unique role. The NCAB advises          (continued on page 2)
                                                               both NCI leadership and the secretary
                                                                                                                                     1 NCI Cancer Bulletin
(Treatment continued from page 1)           with age within stage, but increased        participant in guiding the direction of
after baseline. A comparison of these       with advancing stage of disease,            cancer research.
data points, with consideration of vari-    regardless of age, in both white and        The NCAB’s close affiliation with the
ous cancer risk factors, showed that        black patients. Young women who             President’s Cancer Panel (PCP) also
circulating tumor cells were a useful       are diagnosed with breast cancer, and       sets it apart. In fact, PCP members
predictor of disease progression and        women of all ages who are diagnosed         attend every NCAB meeting, typical-
survival in these women. Analysis also      with breast cancer in its advanced          ly providing an update on the panel’s
showed that five cancer cells per 7.5        stages, are more likely to die from it      activities, but also often engaging in
milliliters of blood was the cutoff for      than from any other cause.                  the board’s discussions.
determining a poor prognosis or the
                                            To develop better estimates of the          Although the NCAB is one small
likelihood of progression-free survival.
                                            risk of death from breast cancer and        group of individuals, through its
Women above the cutoff had a signifi-
                                            other causes in breast cancer pa-           standing and ad hoc subcommit-
cantly shorter survival period—a median
                                            tients, Dr. Schairer and her team ana-      tees and work groups, it can tap into
of 10 months—compared with more
                                            lyzed Surveillance, Epidemiology, and       experts in every aspect of cancer
than 18 months of progression-free
                                            End Results Program data from more          research and treatment, which signifi-
survival for women below the cutoff.
                                            than 400,000 breast cancer patients         cantly expands its ability to thorough-
The authors note that the CellSearch        diagnosed between 1973 and 2000.            ly address the issues brought before
System is not proven as a reliable          They calculated probabilities over a        it. When a subcommittee makes
screening tool for metastatic breast can-   28-year follow-up period according          recommendations (which must first
cer. They do, however, see its promise      to the women’s age at diagnosis, stage      be accepted by the full NCAB), the
as a means of determining treatment         of disease, and race. More recent data      result can often be immediate and
efficacy much earlier than was previ-         allowed additional analysis according       lasting. For example, in February
ously possible—within 3 to 4 weeks of       to tumor size and ER status over an         2003, an NCAB ad hoc working
initiation—compared with the 8 to 12        11-year period.                             group that examined the award
weeks that imaging studies require.
                                            “To our knowledge, this is the first         mechanisms for funding cancer cen-
“This test has the potential to change      comprehensive competing-risk analy-         ters (P30) and Specialized Programs
clinical management,” Dr. Cristofanilli     sis to quantify the probability of death    of Research Excellence, or SPOREs
said in an interview with Reuters           from breast cancer and other causes         (P50) issued an excellent report that
Health. “One day, we may be able to         after a diagnosis of breast cancer,”        included a number of recommenda-
suggest to a patient, based on per-         said Dr. Schairer. “These results can       tions NCI is acting on, including
sonal risk, a more aggressive treat-        provide important prognostic infor-         using cancer centers to pilot new
ment, a less aggressive treatment, or       mation to physicians and patients,          research and dissemination pro-
no treatment at all.”                       and may help in weighing the risks          grams, such as the cancer Biomedical
The second study, published in the          and benefits of various treatment op-        Informatics Grid (caBIG).
September 1 Journal of the National         tions, particularly in older women.”        Under the thoughtful leadership of
Cancer Institute by Dr. Catherine           Dr. Schairer also believes that future      NCAB chair Dr. John Niederhuber,
Schairer and colleagues at the National     studies, such as similar analyses for       I am confident that the NCAB will
Cancer Institute’s (NCI’s) Division of      other cancers and more in-depth             continue to have a positive and last-
Cancer Epidemiology and Genetics,           analyses for breast cancer according to     ing impact on NCI’s activities and the
showed that the probability of death        tumor size and hormone receptor sta-        course of cancer research and care.
from breast cancer varied substan-          tus, could generate additional valuable     The commitment and expertise of the
tially when taking into consideration       tools for physicians and patients. d        NCAB and the other NCI advisory
standard prognostic factors such as                                                     boards are one reason that I am con-
age at diagnosis, tumor size, estro-        (Director’s Update continued from page 1)   fident we can achieve the 2015 goal. d
gen receptor (ER) status, and stage of      provides secondary peer review of           Dr. Andrew C. von Eschenbach
disease. Overall, probability of death      all grant applications to NCI over          Director, National Cancer Institute
from breast cancer relative to death        $50,000. This is a critical responsibili-
from other causes generally declined        ty that ensures the NCAB is an active

2 NCI Cancer Bulletin
                                                                                    later stage tumors, larger tumors,
                                                                                    positive lymph nodes, and tumors
               Cancer Research                                                      with higher histologic and nuclear
                                                                                    grades—all characteristics associated

               Highlights                                                           with a poor outcome. “This study of-
                                                                                    fers new evidence for possible racial/
                                                                                    ethnic differences with regard to p53
                                                                                    alterations,” wrote Dr. Jones.
Selective Use of Patients                more likely than the study group to
from High-Risk Clinics                   have received an intervention. This        In an accompanying editorial, Dr. Lisa
May Bias Study Results                   discrepancy between groups, Dr.            Newman of the Breast Care Center
People who are genetically predis-       Wacholder points out, might cause          at the University of Michigan noted
posed to certain types of cancer can     the study to falsely conclude that the     that ethnic background differences in
undergo treatments and surgeries         controls’ lack of disease is a result of   breast cancer incidence and mortality
that might reduce their risk of dis-     the intervention’s effectiveness. Dr.       are observed worldwide. “The excellent
ease. For example, women who carry       Wacholder recommends that re-              study by Dr. Jones provides an example
a mutation of the BRCA1 or BRCA2         searchers, clinicians, and patients be     of how advances in medical technology
genes are genetically predisposed        wary of results from studies with this     are allowing the oncology community
to breast or ovarian cancer and can      potential bias until researchers can       to explore population-based variation
undergo tubal ligation or prophy-        either eliminate the bias or show that     in breast carcinoma epidemiology on
lactic mastectomy. Research on the       their results are not affected by it.       a more scientific level,” she wrote.
effectiveness of interventions such as    Breast Tumors Found                        Combination Therapy
these can influence what physicians       to be More Aggressive in                   Holds Promise for Prostate
recommend and what individuals ul-       African American Women                     Cancer Patients
timately decide to do. In a commen-      African American women are much            Androgen suppression therapy (AST)
tary in the August 18 Journal of the     more likely to be diagnosed with ag-       combined with standard radiation
National Cancer Institute, Dr. Sholom    gressive breast cancer tumors than         therapy (RT) increases survival in
Wacholder of NCI warns that some         are white women, according to a            men with localized prostate cancer
of these studies may be susceptible      study in the August 9 online issue         when compared to RT alone, accord-
to a bias that can misrepresent the      of Cancer from researchers at Yale         ing to study results reported in the
effectiveness of the interventions.       University School of Medicine, led         August 18 Journal of the American
Clinics that care for people at high     by Dr. Beth Jones. The study found         Medical Association. The prospective
risk for cancer provide a prime set-     that there were racial differences          study was conducted by Dr. Anthony
ting to study an intervention’s effi-      in genetic alterations, with African       D’Amicio and colleagues at Brigham
cacy because these clinics see a large   American women having a greater            and Women’s Hospital and the Dana
number of patients who are carriers      chance of carrying changes in the p53      Farber Cancer Institute in Boston.
of mutated genes. Patients with these    tumor suppressor gene. The study           Previous studies have shown the ben-
mutations who have been diagnosed        was funded by NCI and the U.S.             efits of a 3-year course of combination
with cancer typically serve as the       Department of Defense.                     treatment in men with locally advanced
study group; those who are carriers      While white women have the high-           and high-risk prostate cancer. But,
but have not developed cancer may        est rate of breast cancer, African         AST for more than 1 year is associated
be part of the study’s control group.    American women have the high-              with negative side effects, including
In some studies, controls are recruit-   est death rate of all races from           decreased bone mass; impairment of
ed only from these high-risk clinics     the disease. This anomaly persists         memory, attention, and executive func-
while study group patients are some-     even when adjusting for age, socio-        tions; anemia; muscle loss in exchange
times recruited from sources other       economic status, and disease stage.        for body fat; hot flashes; and impotence.
than high-risk clinics to increase the   The researchers compared tumor             To determine the efficacy of a shorter
number of such patients. As a result,    samples from 145 African American          combination therapy regimen, Dr.
those who were not diagnosed with        women and 177 white women. They            D’Amicio and colleagues recruited
cancer but previously seen at the        found that African American women          (continued on page 4)
clinic—the control group—may be          were significantly more likely to have
                                                                                                        3 NCI Cancer Bulletin
(Research Highlights continued from page 3)   lost productivity and worse quality of    increase in cancer cells’ sensitivity to
206 participants with clinically local-       life than similar individuals without     some drugs. This increase was unex-
ized prostate cancer to this trial,           cancer. “The findings are pretty com-      pected, as MDR1 is perhaps the best-
randomizing them to receive either            pelling, and cancer burden appears to     known multidrug resistance protein.
70 Gy RT alone or the same dose               go beyond the costs of medical care,”     Identification of drugs with increased
of RT combined with 6 months of               says Dr. Yabroff. This study is one        activity in MDR1 expressing tumor
AST. After an average follow-up of            component of NCI’s Health Services        cells raises the exciting possibility of
4.5 years, results projected that the         and Economics Branch’s efforts to          eventually using such compounds
5-year survival rate for patients in the      disseminate data resources to support     against cancers expressing MDR1.
combination-therapy arm would be              policy-relevant research on economic      The researchers advocate further
88 percent, compared to 78 percent            and health services research ques-        investigation in order to discover
for patients in the RT arm. The               tions and improve measurement of          more compounds that may interact in
authors noted that “decreasing AST            cancer burden.                            this way with MDR1 and other ABC
duration could profoundly impact a                                                      transporters.
patient’s quality of life,” and suggested
                                              Research Links Specific
additional avenues of research, such
                                              ABC Transporters and                      The research team has catalogued

as the survival benefits of additional
                                              Drug Efficacy                               information about these drug-gene
                                              NCI scientists have identified associa-    pairs in a database, which is available
radiation sites and higher radiation
                                              tions between expression of individual    at
dosage in combination therapy.
                                              transporters in cancer cells and the      The authors expect the database
High Burden of Illness                        development of resistance, and sensi-     to spur further research into novel
Found in Cancer Survivors                     tivity, to specific drugs. The research,   therapies designed to either evade
Cancer survivors are more likely to           published in the August 22 issue of       or exploit the identified drug-gene
report poorer health than similar             Cancer Cell, details the gene expres-     associations. d
individuals without cancer, according         sion of a 48-member family of mem-
to a study published in the September 1       brane proteins called ABC transport-       NCI to Launch
Journal of the National Cancer Institute.     ers, for which the multidrug resistance    Nanotechnology Initiative
Cancer survivors reported significantly        gene MDR1 is the prototype.                On Monday, September 13 at 1:00
poorer outcomes in both quality of life                                                  p.m., Eastern Time, NCI Director
                                              ABC transporters regulate the traffic
and work productivity. This finding                                                       Dr. Andrew C. von Eschenbach
                                              of molecules—including hormones
was consistent across multiple tumor                                                     will be joined by a panel of experts
                                              and lipids—in and out of cells. Many
types and times since diagnosis.                                                         in nanotechnology to announce
                                              of these 48 proteins transport toxic
“What are the non-medical costs of            materials out of cells, conferring drug    NCI’s Alliance for Nanotechnology
cancer?” asks lead author Dr. Robin           resistance. “Multidrug resistance is       in Cancer, a 5-year initiative to
Yabroff of NCI’s Division of Cancer            a major barrier to effective cancer         explore the potential for integrat-
Control and Population Sciences. To ex-       chemotherapy,” said Dr. Gergely            ing nanotechnology platforms
amine this burden of cancer, Dr. Yabroff       Szakács, one of the study authors,         into cancer research. The Alliance,
and colleagues analyzed data from the         adding “even low levels of resistance      which will include researchers,
2000 National Health Interview Survey.        can have a significant impact on the        clinicians, and public and private
A total of 1,823 cancer survivors and         efficacy of chemotherapy.”                   organizations, will build on exist-
5,469 age-, sex-, and educational at-                                                    ing scientific knowledge to find
                                              The study team, which also included        ways to apply nanotechnology to
tainment-matched control subjects
                                              Drs. Jean-Philippe Annereau, Michael       cancer prevention, detection, di-
were included in the study.
                                              Gottesman, and collaborators in the        agnosis, and treatment. Scientists
While prior cancer burden studies             laboratory of Dr. John Weinstein,          from across the country and
have focused mainly on the costs of           discovered 131 strongly correlated         around the world will participate
treatment, this study focused on two          drug-gene pairs where the expression       in the event, which will be featured
other elements: productivity loss and         of a specific ABC transporter was           live via Webcast at http://video-
quality of life. Even long-term survi-        accompanied by decreased sensitivity For more information,
vors with 11 or more years since diag-        to particular drugs. Conversely, the       go to: d
nosis were more likely to report more         expression of some ABC transport-
                                              ers, most notably MDR1, caused an
4 NCI Cancer Bulletin
A Conversation with Dr. John E. Niederhuber
Dr. John E. Niederhuber, a professor of oncology and surgery at
the University of Wisconsin School of Medicine, was recently
re-appointed as chair of the National Cancer Advisory Board
(NCAB). He was originally appointed in 2002.
                                                                                 School-Based Interventions
What do you see as the NCAB’s primary role or goals?                             To Prevent Obesity
First, obviously, is that the NCAB is advisory. Our goal is to try to help to    PA-04-145
                                                                                 Application Receipt Dates: Nov. 1, 2004;
shape and inform the decision-making process at NCI. As a board made             Mar. 1, 2005; Jul. 1, 2005; Nov. 1, 2005;
                         up of outstanding scientists, clinicians, and leaders   Mar. 1, 2006; Jul. 1, 2006; Nov. 1, 2006;
                         from the lay community who have a vested interest       Mar. 1, 2007; Jul. 1, 2007; Nov. 1, 2007
                         in cancer, that’s our key role.                         This PA encourages the formation of
                       Our second objective is stewardship—to provide            partnerships between academic insti-
                       oversight of NCI’s activities. We need and want to        tutions and school systems in order
                       pay attention to the Institute’s financial manage-         to develop and implement controlled,
                       ment and to programmatic outcomes. We want to             school-based intervention strategies
                       know if NCI is achieving its mission and its specific      designed to reduce the prevalence of
                       goals. We also need to understand whether the             obesity in childhood. This initiative
goals and the programs that have been created in the past are still relevant     also encourages evaluative compari-
to today’s mission and goals. And our third responsibility is advocacy. We       sons of different intervention strate-
need to be active in ensuring that NCI’s visions and successes are com-          gies, as well as the use of methods to
municated to the institute’s key stakeholders, and that includes everybody       detect synergistic interactions be-
from R01 grantees to Congress to the public at large.                            tween different types of interventions.
                                                                                 This PA will use the NIH Research
What do you see as some of the biggest issues facing
                                                                                 Project Grant (R01), Small
NCI and the cancer community?
                                                                                 Grant (R03), and Exploratory/
I think the biggest issue is trying to maximize what we can achieve with         Developmental Grant (R21) award
the budget we are allotted. So we are working as closely as we can with          mechanisms.
NCI leadership to do the sort of forward thinking and planning and tough
                                                                                 For more information see http://cri.
decision-making that maximizes our ability to do the kind of work we
want and need to do.
What role do you think the NCAB can play in that regard?                         Inquiries: Dr. Amy Lazarus Yaroch,
We can do a number of things, but I think one of the most important is 
to serve as good advocates. We need to educate Congress and the public           Pilot and Feasibility Program
about the importance, at this particular point in time, of investing in the      in Urology
science needed to build on the gains we have made in all areas of cancer.        PA-04-146
We really need to tell our story.                                                Application Receipt Dates: Nov. 1, 2004;
                                                                                 Mar. 1, 2005; Jul. 1, 2005; Nov. 1, 2005;
This will be your second term as NCAB chair. Both personally                     Mar. 1, 2006; Jul. 1, 2006; Nov. 1, 2006;
                                                                                 Mar. 1, 2007; Jul. 1, 2007; Nov. 1, 2007
and professionally, what attracts you to this position?
It’s obviously a tremendous honor to be asked to serve as chair for 2 more       The NIDDK and NCI invite applica-
years. It’s a tremendous opportunity for me to reach out to outstanding          tions from investigators with research
scientists and community leaders and actively work with them on some             interests in urology. The primary
of these very important issues. And hopefully, in doing so, we will be an        intent of this initiative is to foster the
important part of moving things forward and making real progress in              development of high-risk pilot and
both preventing cancer and making it something we can manage more                feasibility research by investigators
                                                                                 (continued on page 6)
effectively, to really improve people’s lives. d
                                                                                                      5 NCI Cancer Bulletin
(Funding Opportunities continued from page 5)
developing a new line of research.
Information thus obtained would
allow subsequent submission of R01
                                                                Featured Clinical Trial
applications focusing on research
problems relevant to the study of
urologic diseases and their complica-
tions. This PA replaces PA-02-013.
                                                Prevention of Bone Fractures               “We know that zoledronate inhibits
This PA will use the Exploratory/               in Prostate Cancer Patients                bone resorption and that it reduces
Developmental Grant R21 award                                                              problems such as fractures, spinal
                                                Name of the Trial
mechanism.                                                                                 column compression, and pain as-
                                                Phase III Randomized Study of
For more information see http://cri.            Zoledronate for the Prevention of          sociated with bone metastases,” said          Skeletal-Related Events in Patients        Dr. Smith. “The question this trial is
id=2201                                         With Prostate Cancer and Bone              intended to answer is whether giving
                                                Metastases Undergoing                      zoledronate to patients earlier, while
Inquiries: Dr. Suresh Mohla,
                                                Androgen Deprivation                                    they are still responding
                                                Therapy (CALGB-90202).                                  to androgen deprivation
Cancer Prevention Research Small                                                                        therapy, will result in
Grant Program                                   See the protocol summary
                                                at                             improved outcomes.”
Application Receipt Dates: Dec. 20, 2004;       caltrials/CALGB-90202.                                    Who Can Join This Trial?
Mar. 21, 2005; Jul. 21, 2005; Nov. 21, 2005;
                                                Principal Investigator                                      Researchers seek to
Mar. 22, 2006; Jul. 20, 2006; Nov. 20, 2006;                                                                enroll 680 patients with
Mar. 20, 2007; Jul. 21, 2007; Dec. 20, 2007     Dr. Matthew Smith of Cancer
                                                and Leukemia Group B.                                       confirmed diagnoses
The Division of Cancer Prevention                                                                           of prostate cancer and
of NCI invites applications that                Why Is This Trial Important?
                                                                                                            bone metastases who
address developmental research in               Advanced prostate cancer         Dr. Matthew Smith
                                                                                 Principal Investigator
                                                                                                            are undergoing andro-
chemoprevention agents, biomark-                often spreads to bones, a                                   gen deprivation therapy.
ers, early detection, and nutrition             condition called bone metastases.           See the full list of eligibility criteria
science as well as clinical studies             Men with bone metastases are at risk for this trial at
that focus on specific target organs.            for a variety of complications, includ- clinicaltrials/CALGB-90202.
Small grants are short-term awards              ing fractures, spinal cord compres-
                                                sion, and bone pain. The mainstay           Where Is This Trial Taking Place?
that provide support for pilot proj-
                                                of treatment for metastatic prostate        Study sites in the United States are
ects, development and testing of
                                                cancer is androgen deprivation              recruiting patients for this trial. See
new methodologies, or innovative
                                                therapy, a treatment that markedly          the list of study sites at http://cancer.
projects that provide a basis for more
                                                reduces levels of testosterone and          gov/clinicaltrials/CALGB-90202.
extended research. This PA replaces
PAR-02-176.                                     other androgens (male hormones) in          Who to Contact
                                                the body.                                   See the list of study contacts at http://
This PA will use the NIH Small
                                                This study will evaluate the ability
Grants Program (R03) award
                                                of zoledronate (Zometa), one of a           or call the NCI’s Cancer Information
                                                family of drugs known as bisphos-           Service at 1-800-4-CANCER (1-800-
For more information see http://cri.                                                        422-6237). The call is toll free and
                                                phonates, to prevent fractures and                                                      completely confidential. d
                                                other bone complications when
                                                administered at the same time as or
Inquiries: Dr. Padma Maruvada,                                                             An archive of “Featured Clinical Trial”
                                                shortly following androgen depriva-        columns is available at; Dr. Harold               tion therapy. Currently, zoledronate       clinicaltrials/ft-all-featured-trials.
Seifried,; Dr. Vernon             is given to prostate cancer patients
Steele, d                  after androgen deprivation has
                                                stopped working.

6 NCI Cancer Bulletin
New Information on Prevention Trials          staff resources and financial capital       next generation of research to pro-
Available from NCI                            to provide superior customer service.     mote cancer screening.
Two new easy-to-read brochures                Mr. Elizalde previously worked for        Radiation Oncology Sciences Program
about prevention clinical trials are          the Department of Veterans Affairs         Staff Visit Capitol Hill
now available in English and in               and holds a bachelor’s degree from        On August 17, Dr. C. Norman
Spanish as part of the NCI Clinical           Oklahoma State University, a law de-      Coleman and staff from the NCI
Trials Education Series:                      gree from Oklahoma City University,       Radiation Oncology Sciences Program
If You Want to Find Ways to Prevent           and a master of laws degree from          (ROSP) briefed the House Energy and
Cancer, Learn about Prevention                DePaul University.                        Commerce Committee on the ROSP
Clinical Trials and Si piensa que no hay      Future Directions for Cancer              mission and its components. Staff mem-
forma de prevenir el cáncer...Conozca         Screening Promotion                       bers representing Rep. Michael Bilirakis
los estudios clinicos are for people          The September 1 special issue of          (R-Fla.), Rep. Sherrod Brown (D-Ohio),
considering participation in a preven-        Cancer, titled “Promoting Cancer          and Rep. Chip Pickering (R-Miss.), and
tion clinical trial and are designed to       Screening: Lessons Learned and Future     the American Society for Therapeutic
be used in conjunction with a health          Directions for Research and Practice,”    Radiation Oncology attended.
care professional. The English version        represents a collaborative effort by       The ROSP’s intramural component
is available at   NCI, the American Cancer Society, and     provides clinical care and conducts
trials/learning/about-prevention-trials;      the Centers for Disease Control and       basic and translational research on the
the Spanish version is available at           Prevention (CDC) to identify lessons      use of imaging in radiation therapy           learned from more than 20 years of        and the effects of radiation on healthy
de-prevencion. These and other                cancer screening research and pro-        and cancer cells. A highlight of the
materials can be ordered online at            motion. The papers are intended to        briefing was Dr. Kevin Camphausen’s               encourage and inform future interven-     discussion of participant care in
Elizalde Named Deputy Director                tion research and application efforts.     NCI-run clinical trials. Attendees also
for Management                                The authors point out that multilevel     learned about the telesynergy program
David A. Elizalde was named deputy            approaches to screening, such as          which increases minority access to
director for management (DDM) and             telephone counseling and physician        and participation in radiation clinical
executive officer for NCI, effective             recommendation, offer the greatest         trials, encourages research in cancer
August 22. As DDM, Mr. Elizalde will          potential for improving and sustain-      disparities, and develops new institu-
lead the operations of the Office of            ing screening rates and appropriate       tions within minority communities
Management, including facilitating            follow-up care. They also note that       for long-term research efforts.
and supporting implementation of              future intervention studies should        Reminder: Gerberding to Speak at NIH
NCI initiatives, such as the 2015 chal-       include cost-effectiveness analyses        On Thursday, September 16, at 1:00
lenge goal, advanced technology initia-       and plans for dissemination, and          p.m. in Building 10’s Masur Auditorium
tive, and cancer bioinformatics grid          add that it is not enough to pro-         on the NIH campus, Dr. Julie Louise
(caBIG). Mr. Elizalde comes to NCI            mote the uptake of cancer screening       Gerberding, director of CDC and
from the Centers for Medicare and             tests—practitioners must effectively       administrator of the Agency for Toxic
Medicaid Services, where he served            communicate the benefits and risks         Substances and Disease Registry, will
for the past 5 years as deputy director       of screening tests, as well as test op-   present an NCI Director’s Seminar
of the acquisition and grants group.          tions and limitations, so that people     Series lecture titled, “Achieving Energy
While there, he gained extensive              can make informed decisions about         Balance: Aspiration…Inspiration…
experience in managing acquisitions           cancer screening.                         Motivation… Implementation!” The
for the Medicare prescription drug
                                              Behavioral scientists and other           lecture will be Webcast live at http://
discount card, information technology,
                                              researchers can use the supplement, Sign language
and beneficiary marketing programs.
                                              available at http://www3.interscience.    interpreters will be provided. For more
Throughout his career, he has devel-
                                    ,       information go to
oped innovative and creative solutions
                                              as a point from which to advance the      directorsseminarseries/Gerberding. d
to management challenges, and used
                                                                                                          7 NCI Cancer Bulletin
                    Featured Meetings

   This is a list of selected scientific meetings sponsored by NCI and other organizations. For locations and times
   and a more complete list of scientific meetings, including NCI’s weekly seminars and presentations open to the
   public, see the NCI Calendar of Scientific Meetings at

   NCI Advisory Committee Upcoming Meetings
   Date        Advisory Committee
   Sept. 13-15     NCI Director’s Consumer Liaison Group
   Sept. 14-15     National Cancer Advisory Board
   Sept. 27        President’s Cancer Panel

   Selected Upcoming Meetings of Interest
   Date        Meeting                                                    NCI Speakers
   Sept. 7-8       NIH Leadership Forum                                   Dr. Andrew C. von Eschenbach, Director

   Sept. 9-12      6th National Conference on Changing                    Dr. Joseph F. Fraumeni, Jr., Director,
                   Patterns in Native Communities                         Division of Cancer Epidemiology and Genetics

   Sept. 13        NCI Alliance for Nanotechnology in                     Dr. Andrew C. von Eschenbach, Director;
                   Cancer: Scientific Roundtable                           Dr. Anna Barker, Deputy Director, Advanced
                                                                          Technologies and Strategic Partnerships;
                                                                          Dr. Mauro Ferrari, Special Expert to NCI, Ohio
                                                                          State University

   Sept. 13-14     First International Peritoneal                         Dr. Karen H. Antman, Deputy Director,
                   Mesothelioma Meeting                                   Translational and Clinical Sciences; Dr. Raffit
                                                                          Hassan, Deputy Director, Laboratory of Molecular
                                                                          Biology, Center for Cancer Research; Dr. H. Richard
                                                                          Alexander, Head, Surgical Metabolism Section,
                                                                          Surgery Branch, Center for Cancer Research

   NCI Exhibits
   NCI Exhibits are presented at various professional and society meetings. Further information about
   the NCI Exhibits program can be found at

This NCI Cancer Bulletin is produced by the National Cancer Institute (NCI). NCI,            For more information on cancer,
which was established in 1937, leads a national effort to eliminate the suffering and          call 1-800-4-CANCER or visit
death due to cancer. Through basic and clinical biomedical research and training, NCI
conducts and supports research that will lead to a future in which we can prevent            NCI Cancer Bulletin staff can be reached
cancer before it starts, identify cancers that do develop at the earliest stage, eliminate   at
cancers through innovative treatment interventions, and biologically control those
cancers that we cannot eliminate so they become manageable, chronic diseases.                NIH Publication No. 04-5498

8 NCI Cancer Bulletin

To top